[Impact of COVID-19 Pandemic on Patients with Atopic Dermatitis]. [PDF]
Pourani MR +6 more
europepmc +3 more sources
La dermatitis atópica es una afección crónica, recurrente, no contagiosa, inflamatoria y pruriginosa de la piel, que ocurre con mayor frecuencia en niños, pero también en muchos adultos.
Rosa Irene Alvarado Cuenca +3 more
openalex +3 more sources
Effect of Gabapentin Administered With Prednisolone, Ciclosporin or a Placebo on Clinical Outcomes and Motor Activity in Cats With Atopic Skin Syndrome: A Prospective, Blinded, Placebo-Controlled Study. [PDF]
Background: Gabapentin reportedly decreases central sensitisation, a disorder associated with chronic pruritus in humans, although this is not well documented in cats. Its combined use with the standard antipruritic therapy for feline atopic skin syndrome (FASS) is not yet described.
Morency J +10 more
europepmc +2 more sources
Evaluation of filaggrin 2 expression in dogs with atopic dermatitis before and after oclacitinib maleate administration. [PDF]
Background – Canine atopic dermatitis (cAD) is a chronic, inflammatory, multifactorial and pruritic disease. The presence of skin barrier impairment (e.g. filaggrin alterations), along with abnormal immune responses, can negatively impact cutaneous barrier function.
Villalobos WR +5 more
europepmc +2 more sources
Effect of a Spray Containing Occlusive Agents, Humectants and Physiological Lipids on Skin Hydration of Healthy Dogs When Applied After Bathing With a Chlorhexidine 2%/Miconazole 2% Shampoo. [PDF]
Background: Normal hydration of the canine epidermis is imperative for cutaneous homeostasis. Xerosis may be encountered in canine atopic dermatitis and may be aggravated by topical antiseptics. Hypothesis and Objectives: To evaluate the hydrating properties and the safety of a spray (Sensiderm spray; MP Labo) when applied after shampooing healthy dogs
Pseftogka A +3 more
europepmc +2 more sources
Development of a Four-Language Questionnaire to Investigate Environmental Risk Factors for the Development of Canine Atopic Dermatitis and to Monitor Disease Course and Progression. [PDF]
Background: The chronic and multifactorial character of canine atopic dermatitis (cAD) often leads to poor disease control and treatment dissatisfaction. Environmental factors are likely to contribute to the disease development and may play a more important role than assumed previously.
Rhodius PC +11 more
europepmc +2 more sources
Incidence Rate of Otitis Externa Episodes in Atopic Dogs Is Reduced by a Therapeutic Diet in a 6-Month Randomised, Blinded, Controlled, Clinical Trial. [PDF]
ABSTRACT Background Recurrent otitis externa (OE) episodes commonly affect dogs with canine atopic dermatitis (cAD) despite ongoing cAD treatment. Objective To determine if a therapeutic diet with active ingredients targeting the skin barrier and allergy pathways reduces the incidence rate of OE.
Watson A +5 more
europepmc +2 more sources
An open-label pilot study on an adsorbent mousse containing adelmidrol in client-owned cats with feline atopic skin syndrome and associated seborrhoea. [PDF]
Background – Besides pruritus and skin lesions, cats with feline atopic skin syndrome (FASS) may have seborrhoea. Hypothesis/Objectives – The aim of this pilot study was to investigate whether an adsorbent mousse containing tapioca starch, adelmidrol and a nonpharmacological antimicrobial complex could decrease FASS‐associated seborrhoea in cats ...
Noli C +4 more
europepmc +2 more sources
Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. [PDF]
Background – Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial.
Forster S +4 more
europepmc +2 more sources
Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial. [PDF]
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Forster S +5 more
europepmc +2 more sources

